The Oxford-AstraZeneca COVID-19 vaccine, ChAdOx1, released 4 studies to analyze its efficacy in the prevention of mild, moderate, and severe COVID-19 infection; new studies also address rising concerns in the vaccine’s ability to protect against variants B.1.1.7 and B.1.351.
All articles by Jessica Nye, PhD
Viral load of the COVID-19 in the upper respiratory tract may be an effective stratification method for severe outcomes, length of stay, and death.
Study authors described patients with HIV experiencing virological failure while on long-term ritonavir-boosted darunavir therapy.
Investigators from the CDC determined that the proportion of SARS-CoV-2 transmission in the community is likely to occur from individuals who are asymptomatic.
Study authors quantified SARS-CoV-2 viral load in maternal and neonatal biofluids, tranplacental movement of anti-SARS-CoV-2 antibody, and incidence of fetoplacental infection.
The European Commission on Medical Mycology and International Society for Human and Animal Mycology released clinical guidance and research criteria for managing invasive pulmonary aspergillosis among patients with SARS-CoV-2.
Is there a more convenient and economical procedure for quantifying HIV-1 than by isolating PBMCs?
Children hospitalized with severe anemia where malaria is endemic have a high risk of readmission and death within 6 months after discharge.
William F Wright, MD, and Philip A Mackowiak, MD, discuss the difficulties of utilizing non-contact infrared thermometers for the mass screening of COVID-19 infections.
Study authors compared incident adverse events following remdesivir use in patients without and without severe renal impairment, including hepatotoxicity, nephrotoxicity, mortality, and length of stay.